ESPERION THERAPEUTICS INC (ESPR) Stock News

USA - Nasdaq - NASDAQ:ESPR - US29664W1053 - Common Stock

3.815 USD

+0.04 (+0.93%)

Last: 12/4/2025, 3:50:03 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ESPR Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Stocktwits

Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug

13 days ago - By: Esperion Therapeutics, Inc.

Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

13 days ago - By: Esperion Therapeutics, Inc.

Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

15 days ago - By: Esperion Therapeutics, Inc.

Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference

15 days ago - By: Esperion Therapeutics, Inc.

Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference

a month ago - By: Benzinga - Mentions: STVN PODD AMRK SOLV ...

Earnings Scheduled For November 6, 2025

2 months ago - By: Stocktwits

News Image

Why Is Esperion Therapeutics Stock Sinking Premarket Today?

16 days ago - By: Esperion Therapeutics, Inc.

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

16 days ago - By: Esperion Therapeutics, Inc. - Mentions: HLS.CA

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

24 days ago - By: Esperion Therapeutics, Inc.

Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025

a month ago - By: Zacks Investment Research - Mentions: RDY ANIP ARQT

ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down

a month ago - By: Esperion Therapeutics, Inc.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

a month ago - By: Esperion Therapeutics, Inc.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

a month ago - By: Benzinga - Mentions: AMSC AOSL VAC ACHC ...

DoorDash Posts Downbeat Q3 Earnings, Joins elf Beauty, Duolingo, HubSpot And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

a month ago - By: Esperion Therapeutics, Inc.

Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update

a month ago - By: Esperion Therapeutics, Inc.

Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update

a month ago - By: Esperion Therapeutics, Inc.

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

a month ago - By: Esperion Therapeutics, Inc.

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

a month ago - By: Esperion Therapeutics, Inc.

Esperion to Participate in Jefferies Global Healthcare Conference - London

a month ago - By: Esperion Therapeutics, Inc.

Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.

a month ago - By: Esperion Therapeutics, Inc.

Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.

a month ago - By: Esperion Therapeutics, Inc.

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

a month ago - By: Esperion Therapeutics, Inc.

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

a month ago - By: Esperion Therapeutics, Inc.

Esperion to Report Third Quarter 2025 Financial Results on November 6

2 months ago - By: Zacks Investment Research - Mentions: ANIP EVO CMMB

ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up

2 months ago - By: Esperion Therapeutics, Inc.

Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis

2 months ago - By: Esperion Therapeutics, Inc.

Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis

2 months ago - By: Esperion Therapeutics, Inc.

Esperion Announces Pricing of Public Offering of Common Stock